Aleglitazar is another potent dual PPAR-α/γ agonist that has been proven to significantly improve liver fibrosis and steatosis in patients with type 2 diabetes mellitus and coronary artery disease, characterized by a reduction in liver fat score, fibrosis-4, and NAFLD fibrosis score after 24 months of treatment (Grobbee et al., 2022). The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.